JP6170946B2 - ロミデプシン製剤及びその使用 - Google Patents

ロミデプシン製剤及びその使用 Download PDF

Info

Publication number
JP6170946B2
JP6170946B2 JP2014552325A JP2014552325A JP6170946B2 JP 6170946 B2 JP6170946 B2 JP 6170946B2 JP 2014552325 A JP2014552325 A JP 2014552325A JP 2014552325 A JP2014552325 A JP 2014552325A JP 6170946 B2 JP6170946 B2 JP 6170946B2
Authority
JP
Japan
Prior art keywords
romidepsin
administered
formulation
certain embodiments
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014552325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503623A5 (enExample
JP2015503623A (ja
Inventor
フアング ザ サード リアンフェング
フアング ザ サード リアンフェング
フイ ホ‐ワ
フイ ホ‐ワ
ペイコフ ビクター
ペイコフ ビクター
アール．フォス ウイラード
アール．フォス ウイラード
ナリングレカル ビジャイ
ナリングレカル ビジャイ
ライ メイ
ライ メイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2015503623A publication Critical patent/JP2015503623A/ja
Publication of JP2015503623A5 publication Critical patent/JP2015503623A5/ja
Application granted granted Critical
Publication of JP6170946B2 publication Critical patent/JP6170946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014552325A 2012-01-12 2013-01-11 ロミデプシン製剤及びその使用 Active JP6170946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586066P 2012-01-12 2012-01-12
US61/586,066 2012-01-12
PCT/US2013/021212 WO2013106696A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2015503623A JP2015503623A (ja) 2015-02-02
JP2015503623A5 JP2015503623A5 (enExample) 2016-03-03
JP6170946B2 true JP6170946B2 (ja) 2017-07-26

Family

ID=47604232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552325A Active JP6170946B2 (ja) 2012-01-12 2013-01-11 ロミデプシン製剤及びその使用

Country Status (8)

Country Link
US (3) US20130184225A1 (enExample)
EP (1) EP2802340B1 (enExample)
JP (1) JP6170946B2 (enExample)
CN (1) CN104168908A (enExample)
AU (1) AU2013201937B8 (enExample)
CA (1) CA2863291A1 (enExample)
MX (1) MX2014008390A (enExample)
WO (1) WO2013106696A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630311A (en) * 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106137980B (zh) * 2015-03-31 2021-04-13 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3094721A1 (en) * 2018-04-05 2019-10-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
CN100335122C (zh) * 1999-03-03 2007-09-05 伊莱利利公司 含有成胶束表面活性剂的棘白菌素药物制剂
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
DK2238982T3 (da) * 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
JP2010514802A (ja) * 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンをベースとする癌の処置
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
JP2010105965A (ja) * 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
DK2504353T4 (da) * 2009-11-23 2023-11-20 Cubist Pharmaceuticals Llc Lipopeptidsammensætninger og tilsvarende fremgangsmåder
MY185130A (en) 2010-07-12 2021-04-30 Celgene Corp Romidepsin solid forms and uses thereof

Also Published As

Publication number Publication date
US20130184225A1 (en) 2013-07-18
AU2013201937B8 (en) 2015-08-20
US20150051157A1 (en) 2015-02-19
AU2013201937B2 (en) 2015-07-30
AU2013201937A1 (en) 2013-08-01
MX2014008390A (es) 2014-09-22
WO2013106696A1 (en) 2013-07-18
CA2863291A1 (en) 2013-07-18
JP2015503623A (ja) 2015-02-02
CN104168908A (zh) 2014-11-26
AU2013201937A8 (en) 2015-08-20
EP2802340A1 (en) 2014-11-19
EP2802340B1 (en) 2020-10-28
US20160367625A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
ES2436266T3 (es) Métodos para administrar N-(5-terc-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4-il-etoxi)imidazo[2,1-b][1,3]benzotiazol-2-il]fenil}urea para tratar enfermedades proliferativas
ES2773315T3 (es) Formulación de AC220 secada por pulverización
JP6170946B2 (ja) ロミデプシン製剤及びその使用
EA020354B1 (ru) Пероральные лекарственные формы бендамустина
TW201029661A (en) Compounds
US10548905B2 (en) Amorphous onapristone compositions and methods of making the same
JP6506765B2 (ja) ロミデプシン製剤及びその使用
CN1433310A (zh) 含喜树碱衍生物和pH调节物的药用组合物
JP2023509518A (ja) 安定なシクロデキストリン非含有カルフィルゾミブ配合物
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法
JPH0321252A (ja) シスプラチン高張液
CN117769416A (zh) Bak激活剂、药物组合物和在治疗癌症中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170703

R150 Certificate of patent or registration of utility model

Ref document number: 6170946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250